TWST
Twist BioscienceCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The cleanest post-print positive is operational: 2Q26 revenue beat internal guidance, both DSPS and NGS grew year over year and sequentially, gross margin stayed above 50%, and management raised full-year revenue guidance while reiterating 4Q26 adjusted EBITDA breakeven [#8-K-2026-05-04].
Posture
Mixed
Lead driver
Momentum
What changed
4 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Competition is intense across synthetic biology, gene synthesis, and NGS sample-prep markets, including providers such as GenScript, IDT/Danaher, Thermo Fisher, and Illumina; stronger incumbents can pressure pricing, product breadth, and turnaround times [#10-K-2025-11-17].
Momentum
87
Value
41
Sentiment
26
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $54.00 · Bull $66.00 · Bear $45.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $52.22
Why
Momentum87 · Δ7d +7.7
Value41 · Δ7d +0.1
Sentiment26 · Δ7d -7.2
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
87
34% active weight
Current posture
7d trendSoftening
Δ7d
+7.7
Δ21d
-3.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
26
33% active weight
Current posture
7d trendSoftening
Δ7d
-7.2
Δ21d
-9.7
Why this grade
Composite grade C. Momentum 87.2 / Value 41.1 / Sentiment 25.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$4.23B
Beta
2.23
Shares Out
61.15M
P/E (TTM) · Derived
-53.2
P/S (TTM)
5.58
P/FCF (TTM) · Derived
-54.92
Rev YoY
+16.9%
EPS YoY
+24.0%
Gross Margin
+50.7%
Op Margin
-36.2%
Net Debt
-$232.43M
Current Ratio
3.64
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology

